1. In adults with obesity or overweight with weight-related complications, who have an inadequate response to lifestyle interventions, AGA recommends adding pharmacological agents to lifestyle interventions over continuing lifestyle interventions alone.*
2. In adults with obesity or overweight with weight-related complications, AGA suggests using semaglutide 2.4 mg with lifestyle interventions, compared with lifestyle interventions alone.*
3. In adults with obesity or overweight with weight-related complications, AGA suggests using liraglutide 3.0 mg with lifestyle interventions, compared with lifestyle interventions alone.*
4. In adults with obesity or overweight with weight-related complications, AGA suggests using phentermine-topiramate ER with lifestyle modifications, compared with lifestyle modifications alone.*
5. In adults with obesity or overweight with weight-related complications, AGA suggests using naltrexone-bupropion ER with lifestyle modifications, compared with lifestyle modifications alone.*
6. In adults with obesity or overweight with weight-related complications, AGA suggests against the use of orlistat.*
7. In adults with obesity or overweight with weight-related complications, AGA suggests using phentermine with lifestyle modifications, compared with lifestyle modifications alone.*
8. In adults with obesity or overweight with weight-related complications, AGA suggests using diethylpropion with lifestyle modifications, compared with lifestyle modifications alone.*
9. In adults with BMI between 25 and 40 kg/m2, AGA recommends using Gelesis100 oral superabsorbent hydrogel only in the context of a clinical trial.
*Recommendation includes additional implementation considerations.
